Sustained release and enhanced bioavailability of injectable scutellarin-loaded bovine serum albumin nanoparticles

International Journal of Pharmaceutics

Volumn 476, Issue 1, 2014, Pages 142-148

  Wei, Yuanfeng ^a   Li, Laicun ^a   Xi, Yifeng ^a   Qian, Shuai ^a   Gao, Yuan ^a   Zhang, Jianjun ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Albumin nanoparticles; Bioavailability; Elimination half life; Scutellarin; Sustained release

Indexed keywords

BOVINE SERUM ALBUMIN; NANOPARTICLE; SCUTELLARIN; APIGENIN; DELAYED RELEASE FORMULATION; DRUG CARRIER; GLUCURONIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ELIMINATION HALF-LIFE; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG RELEASE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; APIGENIN; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG LIBERATION; GLUCURONATES; HALF-LIFE; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

EID: 84907933068     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.09.038     Document Type: Article

References (31)

1. P. Arbos, M.A. Campanero, M.A. Arangoa, and J.M. Irache Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines J. Control. Release 96 2004 55 65
2. M. Barzegar-Jalali, K. Adibkia, H. Valizadeh, M.R.S. Shadbad, A. Nokhodchi, Y. Omidi, G. Mohammadi, S.H. Nezhadi, and M. Hasan Kinetic analysis of drug release from nanoparticles J. Pharm. Pharm. Sci. 11 2008 167 177
3. D. Chen, Q. Tang, W. Xue, J. Xiang, L. Zhang, and X. Wang The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles J. Biomed. Res. 24 2010 26 32
4. J. Cortes, and C. Saura Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer EJC Suppl. 8 2010 1 10
5. N. Desai Challenges in development of nanoparticle-based therapeutics AAPS J. 14 2012 282 295
6. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - new applications on the horizon J. Control. Release 157 2012 4 28
7. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
8. R. Foldbjerg, J. Wang, C. Beer, K. Thorsen, D.S. Sutherland, and H. Autrup Biological effects induced by BSA-stabilized silica nanoparticles in mammalian cell lines Chem. Biol. Interact. 204 2013 28 38
9. G. Fotakis, and J.A. Timbrell In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride Toxicol. Lett. 160 2006 171 177
10. Z.X. Gao, D.Y. Huang, H.X. Li, L.N. Zhang, Y.H. Lv, H.D. Cui, and J.H. Zheng Scutellarin promotes in vitro angiogenesis in human umbilical vein endothelial cells Biochem. Biophys. Res. Commun. 400 2010 151 156
11. M. Gaumet, A. Vargas, R. Gurny, and F. Delie Nanoparticles for drug delivery: the need for precision in reporting particle size parameters Eur. J. Pharm. Biopharm. 69 2008 1 9
12. J.M. Huang, W.Y. Weng, X.B. Huang, Y.H. Ji, and E. Chen Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats Eur. J. Drug Metab. Pharmacokinet. 30 2005 165 170
13. Jing, F.B.; Sui, Z.G.; Xu, W.; Liu, D.H.; 2013. Hirudin Albumin Nanoparticles and Preparation Method Thereof. CN 103356485A.
14. A. Jithan, K. Madhavi, M. Madhavi, and K. Prabhakar Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer Int. J. Pharm. Investig. 1 2011 119 125
15. R.S. Kadam, D.W.A. Bourne, and U.B. Kompella Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance Drug Metab. Dispos. 40 2012 1380 1388
16. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
17. M. Li, Y. Zheng, F.Y. Shan, J. Zhou, T. Gong, and Z.R. Zhang Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine Acta Pharmacol. Sinica 34 2013 1108 1115
18. S.D. Li, and L. Huang Pharmacokinetics and biodistribution of nanoparticles Mol. Pharm. 5 2008 496 504
19. Y. Li, X. Zhao, Y. Zu, X. Han, Y. Ge, W. Wang, and X. Yu A novel active targeting preparation, vinorelbine tartrate (vlbt) encapsulated by folate-conjugated bovine serum albumin (BSA) nanoparticles: preparation, characterization and in vitro release study Materials 5 2012 2403 2422
20. L.L. Lin, A.J. Liu, J.G. Liu, X.H. Yu, L.P. Qin, and D.F. Su Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats J. Cardiovasc. Pharmacol. 50 2007 327 332
21. W. Lv, J.X. Guo, J. Li, L.S. Huang, and Q.N. Ping Distribution of liposomal breviscapine in brain following intravenous injection in rats Int. J. Pharm. 306 2005 99 106
22. W.L. Lv, J.X. Guo, Q.N. Ping, Y.M. Song, and J. Li Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats Int. J. Pharm. 359 2008 118 122
23. G.V. Patil Biopolymer albumin for diagnosis and in drug delivery Drug Dev. Res. 58 2003 219 247
24. M. Wang, C. Xie, R.L. Cai, X.H. Li, X.Z. Luo, and Y. Qi Studies on antioxidant activities of breviscapine in the cell-free system Am. J. Chin. Med. 36 2008 1199 1207
25. Y.F. Xi, H. Zhou, L.C. Li, and Y. Gao Central composite design-response surface methodology for the preparation optimization of adsorbed breviscapine by bovine serum albumin nanoparticles J. Chin. Pharm. Univ. 43 2012 216 221
26. W. Xu, R.P. Zha, W.Y. Wang, and Y.P. Wang Effects of scutellarin on PKCgamma in PC12 cell injury induced by oxygen and glucose deprivation Acta Pharmacol. Sinica 28 2007 1573 1579
27. N. Yuksel, A.E. Kanik, and T. Baykara Comparison of in vitro dissolution profiles by ANOVA-based: model-dependent and -independent methods Int. J. Pharm. 209 2000 57 67
28. G.H. Zhang, Q. Wang, J.J. Chen, X.M. Zhang, S.C. Tam, and Y.T. Zheng The anti-HIV-1 effect of scutellarin Biochem. Biophys. Res. Commun. 334 2005 812 816
29. J.J. Zhang, Y.T. Huang, D.P. Liu, Y. Gao, and S. Qian Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement Eur. J. Pharm. Sci. 48 2013 740 747
30. Y. Zhang, M.R. Huo, J.P. Zhou, and S.F. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314
31. D.M. Zhao, X.H. Zhao, Y.G. Zu, J.L. Li, Y. Zhang, R. Jiang, and Z.H. Zhang Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles Int. J. Nanomed. 5 2010 669 677